Prevention of cardiovascular events (eg, death from heart or vascular disease, heart attack, or stroke) in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin - PEGASUS

Exclusion Criteria

• - Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start
• - Persons who have planned coronary, cerebrovascular, or peripheral arterial
• Revascularization (invasive surgery) at study start
• - Persons with known bleeding disorders
• - Persons who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin
• - Persons with a history of ischemic stroke
• - Persons with a history of intracranial bleeding at any time, a tumor or blood vessel abnormality in the brain and/or spinal cord at any time, a history of surgery involving the brain or spinal cord within the last 5 years, or a history of bleeding from the gastrointestinal tract (eg, esophagus, stomach, colon, rectum) within the last 6 months or a major surgery within the last 30 days.
• - Persons considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
• - Persons who have had open heart surgery within the past 5 years, unless the
• person had a heart attack after the surgery
• - Persons with known severe liver disease
• - Persons with kidney failure requiring dialysis
• - Persons with life expectancy < 1 year